AR060130A1 - FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY - Google Patents

FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY

Info

Publication number
AR060130A1
AR060130A1 ARP070101241A ARP070101241A AR060130A1 AR 060130 A1 AR060130 A1 AR 060130A1 AR P070101241 A ARP070101241 A AR P070101241A AR P070101241 A ARP070101241 A AR P070101241A AR 060130 A1 AR060130 A1 AR 060130A1
Authority
AR
Argentina
Prior art keywords
igf
formulation
monoclonal antibody
human monoclonal
preparation
Prior art date
Application number
ARP070101241A
Other languages
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR060130A1 publication Critical patent/AR060130A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion está relacionada con una formulacion de anticuerpo monoclonal humano anti-IGF-1R, un proceso para la preparacion y usos del mismo.The present invention is related to a formulation of anti-IGF-1R human monoclonal antibody, a process for the preparation and uses thereof.

ARP070101241A 2006-03-28 2007-03-26 FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY AR060130A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06111848 2006-03-28

Publications (1)

Publication Number Publication Date
AR060130A1 true AR060130A1 (en) 2008-05-28

Family

ID=37025222

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101241A AR060130A1 (en) 2006-03-28 2007-03-26 FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY

Country Status (18)

Country Link
EP (1) EP1998806A1 (en)
JP (1) JP2009531371A (en)
KR (1) KR20080104160A (en)
CN (1) CN101410137A (en)
AR (1) AR060130A1 (en)
AU (1) AU2007229554A1 (en)
BR (1) BRPI0709229A2 (en)
CA (1) CA2647111A1 (en)
CL (1) CL2007000797A1 (en)
CR (1) CR10295A (en)
EC (1) ECSP088778A (en)
IL (1) IL193904A0 (en)
MA (1) MA30345B1 (en)
MX (1) MX2008012295A (en)
NO (1) NO20083895L (en)
RU (1) RU2008142359A (en)
TW (1) TW200815029A (en)
WO (1) WO2007110339A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007331712A1 (en) * 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
BRPI0809112A2 (en) * 2007-03-22 2014-08-26 Imclone Llc STABLE ANTIBODY FORMULATIONS
CN101687038A (en) * 2007-07-10 2010-03-31 霍夫曼-拉罗奇有限公司 Novel formulation
US20100249384A1 (en) * 2007-11-29 2010-09-30 Stefan Hepbildikler Immunoglobulin aggregates
CN105126099A (en) * 2007-12-21 2015-12-09 弗·哈夫曼-拉罗切有限公司 Antibody formulation
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
BR112012013148A2 (en) * 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag pharmaceutical formulation and use
CN102905692B (en) * 2010-05-28 2015-09-16 诺沃—诺迪斯克有限公司 Comprise the stable multi-dose compositions of antibody and antiseptic
KR102031020B1 (en) 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
CN102363040B (en) * 2011-10-21 2013-05-01 北京锐瑟科技有限公司 Antimicrobial peptide preparation for mucosal tissues
WO2014177460A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
CN103505729B (en) * 2013-05-24 2015-10-28 华北制药集团新药研究开发有限责任公司 A kind of stable rabies virus human antibody combination preparation
CN104707146B (en) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 A kind of pharmaceutical composition containing adalimumab
EP3842455A1 (en) 2014-01-15 2021-06-30 F. Hoffmann-La Roche AG Fc-region variants with improved protein a-binding
CA2950392A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
AR102198A1 (en) 2014-10-09 2017-02-08 Regeneron Pharma PROCESS TO REDUCE SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION
BR112017024610A2 (en) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag specific affinity antitransferrin receptor antibodies
CA2999079A1 (en) * 2015-09-28 2017-04-06 Jiangsu Hengrui Medicine Co., Ltd. Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
RU2753390C1 (en) 2015-10-02 2021-08-13 Ф. Хоффманн-Ля Рош Аг Bispecific antibodies to human cd20/human transferrin receptor and methods for their use
CN106199007B (en) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 Protein protective agent
CN109641050A (en) 2016-08-16 2019-04-16 里珍纳龙药品有限公司 Method for being quantified to the individual antibody in mixture
CN109923411B (en) 2016-10-25 2022-05-31 里珍纳龙药品有限公司 Method and system for chromatographic data analysis
RU2019138507A (en) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. ANTIBODY AGAINST LAG3 AND JOINT ANTIBODY AGAINST LAG3 AND ANTIBODY AGAINST PD-1
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
TW202005694A (en) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 Systems and methods for preparing a polypeptide from a mixture
CN114324882B (en) * 2020-10-12 2022-12-27 广东菲鹏生物有限公司 Protein stabilizer and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2190087T3 (en) * 1997-06-13 2003-07-16 Genentech Inc STABILIZED FORMULATION OF AN ANTIBODY.
CN1854157B (en) * 2001-01-05 2013-01-02 辉瑞大药厂 Antibodies to insulin-like growth factor i receptor
WO2003009817A2 (en) * 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
CA2519113C (en) * 2003-04-02 2012-06-05 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
LT2335725T (en) * 2003-04-04 2017-01-25 Genentech, Inc. High concentration antibody and protein formulations
AR046071A1 (en) * 2003-07-10 2005-11-23 Hoffmann La Roche ANTIBODIES AGAINST RECEIVER I OF THE INSULINAL TYPE GROWTH FACTOR AND THE USES OF THE SAME
DE602004029581D1 (en) * 2003-08-13 2010-11-25 Pfizer Prod Inc MODIFIED HUMANESE IGF-1R ANTIBODIES

Also Published As

Publication number Publication date
IL193904A0 (en) 2011-08-01
KR20080104160A (en) 2008-12-01
AU2007229554A1 (en) 2007-10-04
CA2647111A1 (en) 2007-10-04
TW200815029A (en) 2008-04-01
BRPI0709229A2 (en) 2011-06-28
RU2008142359A (en) 2010-05-10
CL2007000797A1 (en) 2008-01-25
MX2008012295A (en) 2008-10-09
EP1998806A1 (en) 2008-12-10
WO2007110339A1 (en) 2007-10-04
ECSP088778A (en) 2008-10-31
CR10295A (en) 2008-10-06
CN101410137A (en) 2009-04-15
NO20083895L (en) 2008-10-24
JP2009531371A (en) 2009-09-03
MA30345B1 (en) 2009-04-01

Similar Documents

Publication Publication Date Title
AR060130A1 (en) FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY
ECSP10010295A (en) FORMULATION OF ANTIBODY
CR20150625A (en) COMPOSITION UNDERSTANDING ANTIBODY FIXED TO DOMAIN II OF HER2 AND ITS VARIOUS ACIDS
AR057807A1 (en) ANTI-CD3 ANTIBODY FORMULATIONS
CR20120310A (en) NEUTRALIZING ANTIBODIES AGAINST THE PROLACTIN RECEPTOR AND THERAPEUTIC USE
CR20120215A (en) ANTIBODIES AGAINST HUMAN CSF-1R AND USES OF THE SAME
EA201200551A1 (en) PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSED FORM, METHODS OF THEIR PRODUCTION AND APPLICATION FOR TREATMENT
CR20110091A (en) NEUTRALIZING ANTIBODIES OF HUMAN CITOMEGALOVIRUS AND USE OF THE SAME
PA8660301A1 (en) PIRAZOLO PIRIDINAS REPLACED, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCEDURE
CO7151488A2 (en) Anti-jagged1 / jagged 2 cross-reaction antibodies, activatable anti-jagged antibodies and methods of use thereof
ECSP13012877A (en) SOLID FORMS SDE 3- (5-AMINO-2-methyl -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, AND ITS PHARMACEUTICAL COMPOSITIONS AND USES
EA200900040A1 (en) ANTIBODY MOLECULES THAT ASSOCIATE WITH HUMAN IL-17
CL2019001745A1 (en) Conjugated antibody drug for ablation of hematopoietic stem cells.
ECSP14000329A (en) MOLECULES THAT ARE ANTIBODIES WITH SPECIFICITY FOR HUMAN OX40
CR10528A (en) PROCESS TO PRODUCE POXVIRUS AND POXVIRUS COMPOSITIONS
PA8772101A1 (en) IMIDAZOL-TRIAZOLOPIRIMIDINAS REPLACED
AR051484A1 (en) ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR IL - 17 HUMAN
AR057224A1 (en) ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR HUMAN IL-6
EA201001577A1 (en) DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PRODUCTION
PA8770101A1 (en) AMIDAS OF 4-ARIL-1,4-DIHIDRO-1, 6-NAFTIRIDINE SUBSTITUTED AND ITS USE
UA116999C2 (en) Anti-hemagglutinin antibodies and methods of use
BR112012032008A2 (en) s100a4 antibodies and therapeutic uses thereof
CR10561A (en) VACCINES FOR MALARIA
BRPI1014544B8 (en) isolated fully human monoclonal anti-il-17f antibody and pharmaceutical composition comprising the same
ES2408343R1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone

Legal Events

Date Code Title Description
FA Abandonment or withdrawal